Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK comparability of pivotal-process vs commercial-process turoctocog alfa pegol in severe haemophilia A
NL-OMON42941Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of octocog alfa in hemophilia A (2 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the FVIII activity-time curve from 0 to 96 hours post injection. Started Jan 2017; status: active, not recruiting.
02
Drugs
octocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON42941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42941.